Company news

Alnylam Pharmaceuticals, Inc. news in 2025

Alnylam Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues

December 18, 2025

Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics

December 16, 2025

Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

December 16, 2025

Annual Changes to the Nasdaq-100 Index®

December 12, 2025

Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

December 10, 2025

Alnylam Pharmaceuticals Announces Changes to Board of Directors

December 2, 2025

New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

November 7, 2025

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 3, 2025

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

October 29, 2025

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

October 15, 2025

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

September 30, 2025

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

September 27, 2025

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

September 8, 2025

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

September 7, 2025

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

August 30, 2025

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

August 30, 2025

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

August 29, 2025

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

August 29, 2025

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

August 26, 2025

Scenic Enters License and Research Agreement with Alnylam

August 26, 2025

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

August 10, 2025

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

August 4, 2025

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

July 30, 2025

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

July 16, 2025

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

July 2, 2025

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

June 17, 2025

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

June 8, 2025

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025

Alnylam Issues 2024 Corporate Responsibility Report

May 19, 2025

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

May 16, 2025

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

May 11, 2025

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

May 4, 2025

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

April 30, 2025

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

April 27, 2025

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

April 16, 2025

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

March 31, 2025

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

March 28, 2025

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

March 27, 2025

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

March 19, 2025

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

March 10, 2025

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

March 4, 2025

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

February 24, 2025

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

February 12, 2025

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

January 29, 2025

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

January 11, 2025

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025